| Here's Why Penumbra (PEN) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-15 14:56:16 |
Czytaj oryginał (ang.) |
| Here's Why Penumbra (PEN) is a Strong Growth Stock |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. |
zacks.com |
2025-05-14 14:50:48 |
Czytaj oryginał (ang.) |
| 3 Mid-Cap Medical Stocks Outperforming the Market |
While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance. |
marketbeat.com |
2025-05-06 16:50:17 |
Czytaj oryginał (ang.) |
| Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference |
ALAMEDA, Calif. , April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. |
prnewswire.com |
2025-04-29 20:30:00 |
Czytaj oryginał (ang.) |
| Baron Health Care Fund Q1 2025 Top Net Purchases And Sales |
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst. |
seekingalpha.com |
2025-04-29 15:45:00 |
Czytaj oryginał (ang.) |
| Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-04-29 14:50:41 |
Czytaj oryginał (ang.) |
| 3 Reasons Growth Investors Will Love Penumbra (PEN) |
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2025-04-28 17:45:37 |
Czytaj oryginał (ang.) |
| Why Penumbra (PEN) is a Top Growth Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-04-28 14:50:42 |
Czytaj oryginał (ang.) |
| Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst |
Penumbra Inc PEN stock is trading higher after the company reported better-than-expected first-quarter 2025 earnings and reaffirmed the 2025 forecast. |
benzinga.com |
2025-04-24 19:27:03 |
Czytaj oryginał (ang.) |
| Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand |
PEN reports better-than-expected earnings and revenues in the first quarter of 2025. |
zacks.com |
2025-04-24 15:45:44 |
Czytaj oryginał (ang.) |
| Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript |
Penumbra, Inc. (NYSE:PEN ) Q1 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Cecilia Furlong - Business Development & IR Adam Elsesser - Chairman & CEO Maggie Yuen - CFO Jason Mills - EVP, Strategy Conference Call Participants Robbie Marcus - JPMorgan Lei Huang - Wells Fargo Pito Chickering - Deutsche Bank Macauley Kilbane - William Blair Bill Plovanic - Canaccord Travis Steed - Bank of America Ryan Zimmerman - BTIG Kallum Titchmarsh - Morgan Stanley Richard Newitter - Truist Matthew O'Brien - Piper Sandler David Rescott - Baird Operator Good afternoon. My name is Tameka and I will be your conference operator today. |
seekingalpha.com |
2025-04-24 00:15:41 |
Czytaj oryginał (ang.) |
| Penumbra (PEN) Reports Q1 Earnings: What Key Metrics Have to Say |
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-04-23 23:00:39 |
Czytaj oryginał (ang.) |
| Penumbra (PEN) Q1 Earnings and Revenues Top Estimates |
Penumbra (PEN) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.41 per share a year ago. |
zacks.com |
2025-04-23 22:15:33 |
Czytaj oryginał (ang.) |
| Penumbra, Inc. Reports First Quarter 2025 Financial Results |
ALAMEDA, Calif. , April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. |
prnewswire.com |
2025-04-23 20:05:00 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Penumbra, Inc. (NYSE: PEN) and Encourages Current Penumbra Shareholders to Contact the Firm |
PHILADELPHIA, April 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Kaskela Law LLC is investigating Penumbra, Inc. (NYSE: PEN) on behalf of the company's current shareholders. |
globenewswire.com |
2025-04-21 21:20:00 |
Czytaj oryginał (ang.) |
| Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again |
Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-04-21 17:15:41 |
Czytaj oryginał (ang.) |
| Penumbra (PEN) Earnings Expected to Grow: Should You Buy? |
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-16 15:06:35 |
Czytaj oryginał (ang.) |
| Reasons to Retain Penumbra Stock in Your Portfolio for Now |
PEN continues to attract investor interest with its strong Thrombectomy business and portfolio expansion efforts. |
zacks.com |
2025-04-08 15:00:41 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Penumbra, Inc. (NYSE: PEN) |
NEW YORK , April 8, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Penumbra, Inc. (NYSE: PEN) on behalf of the company's shareholders. The investigation seeks to determine whether Penumbra's directors breached their fiduciary duties in connection with recent corporate actions. |
prnewswire.com |
2025-04-08 12:00:00 |
Czytaj oryginał (ang.) |
| Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 |
ALAMEDA, Calif. , April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. |
prnewswire.com |
2025-04-03 20:30:00 |
Czytaj oryginał (ang.) |
| Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors |
ALAMEDA, Calif. , Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. |
prnewswire.com |
2025-02-21 18:05:00 |
Czytaj oryginał (ang.) |
| Penumbra (PEN) Upgraded to Buy: Here's Why |
Penumbra (PEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-02-20 15:00:35 |
Czytaj oryginał (ang.) |
| Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises |
Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024. |
zacks.com |
2025-02-19 10:16:11 |
Czytaj oryginał (ang.) |
| Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript |
Penumbra, Inc. (NYSE:PEN ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Larry Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Bill Plovanic - Canaccord Richard Newitter - Truist Securities Samantha Kurtz - Piper Sandler Michael Sarcone - Jefferies Ryan Zimmerman - BTIG Shagun Singh - RBC Capital Markets Michael Kratky - Leerink Partners Operator Good afternoon. My name is Rob and I will be your conference operator today. |
seekingalpha.com |
2025-02-19 01:04:03 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings |
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-18 21:01:13 |
Czytaj oryginał (ang.) |
| Penumbra (PEN) Beats Q4 Earnings and Revenue Estimates |
Penumbra (PEN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.76 per share a year ago. |
zacks.com |
2025-02-18 20:20:14 |
Czytaj oryginał (ang.) |
| Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results |
ALAMEDA, Calif. , Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. |
prnewswire.com |
2025-02-18 18:05:00 |
Czytaj oryginał (ang.) |
| Should You Add Penumbra Stock to Your Portfolio Right Now? |
PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts. |
zacks.com |
2025-02-12 09:36:09 |
Czytaj oryginał (ang.) |
| Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025 |
ALAMEDA, Calif. , Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time. |
prnewswire.com |
2025-01-21 18:30:00 |
Czytaj oryginał (ang.) |
| Buy 4 Low-Beta Stocks AVO, TXO, PEN & STRA to Beat Market Volatility |
It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. AVO, TXO, PEN & STRA are well-poised to gain. |
zacks.com |
2025-01-17 17:46:30 |
Czytaj oryginał (ang.) |
| 3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN) |
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2025-01-16 15:46:20 |
Czytaj oryginał (ang.) |
| 5 Must-Buy Efficient Stocks to Increase Your Portfolio Returns |
Invest in companies like YPF, TEF, PEN, DECK and ANF to make the most of higher efficiency levels. |
zacks.com |
2025-01-15 10:51:10 |
Czytaj oryginał (ang.) |
| Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains? |
Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-01-08 08:10:24 |
Czytaj oryginał (ang.) |
| Reasons to Add Penumbra Stock to Your Portfolio Now |
PEN stays on investors' radars due to its strong Thrombectomy business and international growth plans. |
zacks.com |
2025-01-07 09:55:25 |
Czytaj oryginał (ang.) |
| IART or PEN: Which Is the Better Value Stock Right Now? |
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2025-01-06 14:46:17 |
Czytaj oryginał (ang.) |
| Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
ALAMEDA, Calif. , Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P. |
prnewswire.com |
2024-12-30 18:30:00 |
Czytaj oryginał (ang.) |
| Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes" |
Penumbra (PEN) could produce exceptional returns because of its solid growth attributes. |
zacks.com |
2024-12-25 15:46:10 |
Czytaj oryginał (ang.) |
| Here's Why Penumbra (PEN) is a Strong Growth Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-23 12:46:13 |
Czytaj oryginał (ang.) |
| 4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2025 |
Investing in large-cap MedTech stocks like MCK, PEN, CAH and PEN can be profitable for investors in 2025. |
zacks.com |
2024-12-20 12:26:08 |
Czytaj oryginał (ang.) |
| Here's Why Penumbra (PEN) is a Strong Momentum Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-18 12:51:20 |
Czytaj oryginał (ang.) |
| Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst |
Shares of Penumbra Inc PEN recovered slightly in early trading on Tuesday, after a week of correction. |
benzinga.com |
2024-12-17 13:03:40 |
Czytaj oryginał (ang.) |
| 3 Medical Instruments Industry Stocks to Buy on the GenAI Wave |
MASI, PEN and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar their prospects. |
zacks.com |
2024-12-16 14:16:19 |
Czytaj oryginał (ang.) |
| Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why |
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2024-12-09 15:46:19 |
Czytaj oryginał (ang.) |
| Why Penumbra (PEN) is a Top Growth Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-12-06 12:50:26 |
Czytaj oryginał (ang.) |
| Is Penumbra Stock a Smart Buy for Your Portfolio Right Now? |
PEN stays on investors' radars due to its robust portfolio expansion and international growth plans. |
zacks.com |
2024-12-03 10:01:20 |
Czytaj oryginał (ang.) |
| GMED vs. PEN: Which Stock Should Value Investors Buy Now? |
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2024-11-29 14:46:29 |
Czytaj oryginał (ang.) |
| Why Is Penumbra (PEN) Up 6.7% Since Last Earnings Report? |
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-11-29 14:36:41 |
Czytaj oryginał (ang.) |
| Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-26 12:55:29 |
Czytaj oryginał (ang.) |
| 3 Reasons Growth Investors Will Love Penumbra (PEN) |
Penumbra (PEN) possesses solid growth attributes, which could help it handily outperform the market. |
zacks.com |
2024-11-21 15:46:10 |
Czytaj oryginał (ang.) |
| Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference |
ALAMEDA, Calif. , Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. |
prnewswire.com |
2024-11-20 18:30:00 |
Czytaj oryginał (ang.) |
| Here is Why Growth Investors Should Buy Penumbra (PEN) Now |
Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials. |
zacks.com |
2024-11-05 15:46:32 |
Czytaj oryginał (ang.) |
| Here's Why Penumbra (PEN) is a Strong Momentum Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-05 12:51:11 |
Czytaj oryginał (ang.) |
| New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options |
Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system ALAMEDA, Calif. , Nov. 5, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra's computer assisted vacuum thrombectomy (CAVT™) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other treatment options. |
prnewswire.com |
2024-11-05 11:00:00 |
Czytaj oryginał (ang.) |
| Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market |
The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business. |
zacks.com |
2024-10-31 11:50:32 |
Czytaj oryginał (ang.) |
| Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript |
Penumbra, Inc. (NYSE:PEN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Richard Newitter - Truist Securities Robert Marcus - JPMorgan Joanne Wuensch - Citi Michael Sarcone - Jefferies Samantha Kurtz - Piper Sandler Michael Kratky - Leerink Pito Chickering - Deutsche Bank Michael Matson - Needham Operator Good afternoon. My name is Jeremy, and I will be your conference operator today. |
seekingalpha.com |
2024-10-31 01:45:27 |
Czytaj oryginał (ang.) |